Abstract: ETV6 gene abnormalities are well described in tumor pathology. Many fusion partners of ETV6 have been reported in a variety of epithelial, mesenchymal, and hematological malignancies. In salivary gland tumor pathology, however, the ETV6-NTRK3 translocation is specific for (mammary analog) secretory carcinoma, and has not been documented in any other salivary tumor type. The present study comprised a clinical, histologic, and molecular analysis of 10 cases of secretory carcinoma, with typical morphology and immunoprofile harboring a novel ETV6-RET translocation.
(M ammary analog) secretory carcinoma of salivary gland origin is a recently described tumor that harbors a characteristic balanced t(12;15)(p13;q25) chromosomal translocation resulting in an ETV6-NTRK3 fusion 1 identical to that commonly found in secretory carcinoma (SC) of the breast. 2 The ETV6-NTRK3 fusion gene encodes a chimeric tyrosine kinase with transforming activity in epithelial and myoepithelial cells in the mouse mammary gland. 3 Over many years, Skalova et al 1 began to identify a distinctive, hitherto unrecognized neoplasm arising in the salivary glands characterized by morphologic and immunohistochemical features strongly reminiscent of those of SC of the breast. These salivary carcinomas are composed of microcystic and solid areas with abundant vacuolated colloid-like periodic acid-Schiff-positive secretory material within the microcystic spaces. These tumors had previously been categorized as either unusual variants of salivary acinic cell carcinoma (AciCC) or adenocarcinoma not otherwise specified. 1 Salivary SC was initially recognized as an entity different from AciCC on the basis of 3 major findings. 1 First, SC showed no basophilia in the cytoplasm of any of the constituent cells, which is the hallmark of the serous acinar cells of AciCC resulting from the presence of cytoplasmic zymogen granules. Second, these neoplasms had a completely different immunohistochemical profile, almost always expressing S100 protein, mammaglobin, vimentin, STAT5, and MUC4, all of which are rarely expressed in AciCC. Finally, SCs were found to harbor an ETV6-NTRK3 fusion gene due to a t(12; 15)(p13,q25) translocation, a finding identical to SC of the breast 2 and absent in AciCCs. 1 Because of the morphologic similarities and identical ETV6-NTRK3 fusion transcripts, the designation "mammary analog secretory carcinoma of salivary gland" has been proposed, 1 and the name was widely accepted and used in the literature. The most recent version of the World Health Organization Classification of Head and Neck Tumors, however, utilizes the terminology "secretory carcinoma" 4 for consistency, and because SCs have been recently described at other extrasalivary and extramammary sites, such as thyroid gland, [5] [6] [7] [8] skin, 9, 10 and sinonasal mucosa. 11 The presence of the ETV6-NTRK3 fusion gene has not been demonstrated in any other salivary gland tumor, but the same translocation can be seen not only in SC of breast, 2 but also in infantile fibrosarcoma, 12 congenital mesoblastic nephroma, 13 certain hematopoietic malignancies, 14 ALKnegative inflammatory myofibroblastic tumors, 15 a small subset of gastrointestinal stromal tumors, 16 and in radiation-induced papillary thyroid carcinomas. 17 Moreover, ETV6-NTRK3 translocated papillary thyroid cancers have been recently described in adult patients with no history of radiation exposure. 18 The near 100% rate of ETV6 gene rearrangement in SC has been subsequently confirmed by many other studies. [19] [20] [21] [22] [23] [24] [25] Detection of ETV6 rearrangements by fluorescent in situ hybridization (FISH) or the ETV6-NTRK3 fusion by reversetranscriptase polymerase chain reaction (RT-PCR) in formalin-fixed paraffin-embedded (FFPE) material is technically relatively straightforward and > 300 cases of SC have been published since its original description.
Up until now, in all published cases of SC where the fusion partner is identified, ETV6 is fused with NTRK3, and no other fusion partners have been reported so far. Nevertheless, for several years, we have been aware of several SC cases positive for the ETV6 gene split as visualized by FISH, but in which the classic ETV6-NTRK3 fusion transcript (exon 5-exon 15 junction) was not detected by standard RT-PCR. A subset of SCs showing ETV6 rearrangements with so far unknown partners have been recently reported and provisionally called ETV6-X translocated SCs, 26 in agreement with a study of Ito et al, 27 who found 2 such cases. In the present study using the next-generation sequencing (NGS) as a diagnostic platform, we describe 10 cases morphologically and immunohistochemically typical of SC, harboring a novel ETV6-RET translocation.
MATERIALS AND METHODS
Among > 4500 cases of primary salivary gland tumors, 194 cases of SCs were retrieved from the consultation files of the Salivary Gland Tumor Registry, at For conventional microscopy, the excised tissues were fixed in formalin, routinely processed, embedded in paraffin (FFPE), cut, and stained with hematoxylin and eosin. In most cases, additional stains were also performed, including periodic acid-Schiff with and without diastase, mucicarmine, and alcian blue at pH 2.5.
For immunohistochemical studies, 4 μm thick sections were cut from paraffin blocks and mounted on positively charged slides (TOMO, Matsunami Glass Ind., Japan). Sections were processed on a BenchMark UL-TRA (Ventana Medical System, Tucson, AZ), deparaffinized, and then subjected to heat-induced epitope retrieval by immersion in a CC1 solution at pH 8.6 at 95°C. After antigen retrieval, sections were stained with a pan-RTK antibody cocktail consisting of rabbit monoclonal antibodies, all obtained from Cell Signaling (Danvers, MA), targeting pan-Trk (A7H6R, active against TrkA, TrkB, and TrkC, 1:50 dilution), ROS1 (D4D6, 1:50), and ALK (D5F3, 1:50), as described previously. 28 All other primary antibodies used are summarized in Table 1 . The bound antibodies were visualized using the ultraView Universal DAB Detection Kit (Roche) and ultraView Universal Alkaline Phosphatase Red Detection Kit (Roche). The slides were counterstained with the Mayer hematoxylin. Appropriate positive and negative controls were used.
Clinical follow-up was obtained from the patients, their physicians, or from referring pathologists.
Molecular Genetic Study Detection of ETV6-NTRK3 and ETV6-RET Fusion Transcripts by RT-PCR
RNA was extracted using the RecoverAll Total Nucleic Acid Isolation Kit (Ambion, Austin, TX). cDNA was synthesized using the Transcriptor First Strand cDNA Synthesis Kit (RNA input 500 ng; Roche Diagnostics, Mannheim, Germany). All procedures were performed according to the manufacturer's protocols. Amplification of a 105 and 133 bp product of the μ2-microglobulin gene and 247 bp product of the PGK gene was used to test the quality of the extracted RNA as previously described. [29] [30] [31] A detection of classic exon 5 of ETV6 gene and exon 15 of NTRK3 gene, 32 as well as atypical exon 4 of the ETV6 gene and exon 14 of the NTRK3 gene (and their combinatorial variants) fusion transcript was performed by RT-PCR. In addition, more sensitive, nested RT-PCR was performed for the detection of classic 26, 27 as well as selected atypical junction of transcripts. Except that, RT-PCR for ETV6-RET fusion transcript detection was also carried out after receiving of the NGS results.
For single-round PCR, 2 L of cDNA was added to reaction consisting of 12.5 μL of HotStar Taq PCR Master Mix (QIAgen, Hilden, Germany), 10 pmol of each primer (Table 2) , and distilled water up to 25 μL. The amplification program comprised denaturation at 95°C for 14 minutes and then 45 cycles of denaturation at 95°C for 1 minute, annealing at temperature seen in Table 2 for 1 minute and extension at 72°C for 1 minute. The program was finished by incubation at 72°C for 7 minutes. For nested PCR, the same reaction conditions were utilized. One microliter of PCR product from the first round was used as a template.
Successfully amplified PCR products were purified with magnetic particles of Agencourt AMPure (Agencourt Bioscience Corporation, A Beckman Coulter Company, Beverly, MA). Products were then bidirectionally sequenced using Big Dye Terminator Sequencing Kit (Applied Biosystems, Foster City, CA), and purified with magnetic particles of Agencourt CleanSEQ (Agencourt Bioscience Corporation), all according to the manufacturer's protocol, and run on an automated sequencer ABI Prism 3130xl (Applied Biosystems) at a constant voltage of 13.2 kV for 11 minutes.
Detection of Alteration of ETV6, NTRK3, and RET Genes by FISH Method
Four-micrometer-thick FFPE sections were placed onto positively charged slides. Hematoxylin and eosinstained slides were examined for determination of areas for cell counting. The unstained slides were routinely deparaffinized and incubated in the ×1 Target Retrieval Solution Citrate pH 6 (Dako, Glostrup, Denmark) at 95°C for 40 minutes and subsequently cooled for 20 minutes at room temperature in the same solution. Slides were washed in deionized water for 5 minutes and digested in protease solution with Pepsin (0.5 mg/mL; Sigma Aldrich, St Louis, MO) in 0.01 M HCl at 37°C for 25 to 60 minutes, according to the sample conditions. Slides were then placed into deionized water for 5 minutes, dehydrated in a series of ethanol solutions (70%, 85%, 96% for 2 min each), and air dried.
Two commercial probes were used for the detection of rearrangement of ETV6 and RET genes, Vysis ETV6 Break Apart FISH Probe Kit (Vysis/Abbott Molecular, IL) and ZytoLight SPEC RET Dual Color Break Apart Probe (ZytoVision GmbH, Bremerhaven, Germany). ETV6 probe was mixed with water and LSI/WCP (LocusSpecific Identifier/Whole Chromosome Painting) Hybridization buffer (Vysis/Abbott Molecular) in a 1:2:7 ratio, respectively. RET probe was factory premixed.
Probes for detection of rearrangement of NTRK3 gene region and ETV6-RET genes fusion were mixed from custom designed SureFISH probes (Agilent Technologies Inc., Santa Clara, CA). Chromosomal regions for NTRK3 break-apart probe oligos are chr15:87501469-88501628 and chr15:88701444-89700343; for ETV6-RET fusion probe, chr12:11675872-12175711 and chr10:43354893-43849282. Probe mixture was prepared from corresponding probes (each color was delivered in a separate well), deionized water, and LSI Buffer (Vysis/Abbott Molecular) in a 1:1:1:7 ratio, respectively.
An appropriate amount of mixed and premixed probes was applied on specimens, covered with a glass coverslip, and sealed with rubber cement. Slides were incubated in the ThermoBrite instrument (StatSpin/Iris Sample Processing, Westwood, MA) with codenaturation at 85°C for minutes and hybridization at 37°C for hours. Rubber cemented coverslip was then removed and the slide was placed in posthybridization wash solution (2×SSC/0.3% NP-40) at 72°C for 2 minutes. The slide was air dried in the dark, counterstained with 4′,6′-diamidino-2-phenylindole DAPI (Vysis/Abbott Molecular), coverslipped, and immediately examined.
FISH Interpretation
The sections were examined with an Olympus BX51 fluorescence microscope (Olympus Corporation, Tokyo, Japan) using a ×100 objective and filter sets Triple Band Pass (DAPI/SpectrumGreen/SpectrumOrange), Dual Band Pass (SpectrumGreen/SpectrumOrange), and Single Band Pass (SpectrumGreen or SpectrumOrange). (Table 6) . †Stevens et al 8 ( Table 2 ).
For each probe, 100 randomly selected nonoverlapping tumor cell nuclei were examined for the presence of yellow or green and orange fluorescent signals. Regarding break-apart probes, yellow signals were considered negative, and separate orange and green signals were considered positive; conversely, for fusion probe, yellow signals were considered positive, and separate orange and green signals were considered negative.
Cutoff values were set to > 10% and 20% of nuclei (break-apart and fusion probes, respectively) with chromosomal breakpoint signals (mean, +3 SD rounded up in normal non-neoplastic control tissues).
Sample Preparation for NGS
For NGS studies, 2 to 3 FFPE sections (10 µm thick) were macrodissected to isolate tumor-rich regions. Samples were extracted for total nucleic acid using Agencourt FormaPure Kit (Beckman Coulter, Brea, CA) following the corresponding protocol with an overnight digest and an additional 80°C incubation as described in modification of the protocol by ArcherDX (ArcherDX Inc., Boulder, CO). Total nucleic acid was quantified using the Qubit Broad Range RNA Assay Kit (Thermo Fisher Scientific) and 2 µL of sample.
RNA Integrity Assessment and Library Preparation for NGS
Unless otherwise indicated, 250 ng of FFPE RNA was used as input for NGS studies. To assess RNA quality, the PreSeq RNA QC Assay using iTaq Universal SYBR Green Supermix (Biorad, Hercules, CA) was performed on all samples during library preparation to generate a measure of the integrity of RNA (in the form of a cycle threshold value). Library preparation and RNA QC were performed following the Archer Fusion Plex Protocol for Illumina (ArcherDX Inc.). A custom primer set with 28 primers spanning regions on 3 specific genes of interest, including all 8 exons of ETV6 gene in 3′ direction, was designed and used. Final libraries were diluted 1:100,000 and quantified in a 10 µL reaction following the Library Quantification for Illumina Libraries protocol and assuming a 200 bp fragment length (KAPA, Wilmington, MA). The concentration of final libraries was around 200 nM. The threshold representing the minimum molar concentration for which sequencing can be robustly performed was set at 50 nM.
NGS and Analysis
Libraries were sequenced on a MiSeq sequencer (Illumina, San Diego, CA). They were diluted to 4 nM and equal amounts of up to 16 libraries were pooled per run. The optimal number of raw reads per sample was set to 500,000. Library pools were diluted to 16 pM library stock with 5% 12.5 pM PhiX and loaded into the MiSeq cartridge. Analysis of sequencing results was performed using the Archer Analysis software (v5; ArcherDX Inc.). Fusion parameters were set to a minimum of 5 valid fusion reads with a minimum of 3 unique start sites within the valid fusion reads.
RESULTS

Molecular Genetic Findings
Selected 30 cases of SC (as described earlier) were analyzed by NGS using the ArcherDX analysis platform. This analysis detected a novel ETV6-RET fusion transcript joining exon 6 of ETV6 gene and exon 12 of RET gene in 10 cases of salivary gland tumors displaying histologic and immunohistochemical features typical of SC (Fig. 1) . All but 1 ETV6-RET positive SC case were then tested by at least 1 FISH probe for the presence of ETV6-RET rearrangements (Fig. 2) . In case 9, there was no residual tissue material for confirmation of the NGS analysis by FISH tests. In addition, RT-PCR for the confirmation of the presence of ETV6-RET fusion transcript followed by Sanger sequencing on positive samples was performed in all 10 cases (Fig. 1) . The results of the NGS tests, details of the analysis, and results of confirmatory genetic tests are summarized in Tables 3 and  4 . In addition, NGS analysis resulted in detection of the ETV6-NTRK3 fusion in 15 SC cases. In 4 cases, NGS revealed negative results, and 1 case was unanalyzable (detailed data not shown). No other fusion transcripts different from ETV6-NTRK3 or ETV6-RET were found by NGS in any analyzable case of SC.
Clinical and Histologic Characteristics of the Study Group
The clinical and follow-up data of 10 patients with ETV6-RET translocated SC of salivary glands are summarized in Table 5 . There were 3 female and 7 male patients. The median patient age was 40.8 years, with a range between 20 and 77 years. The most common anatomic site of involvement was the parotid gland, occurring in 7 patients. Other primary sites of the origin included the submandibular gland and minor salivary gland of the upper lip in 2 patients and 1 patient, respectively.
Follow-up Data
Clinical follow-up data were obtained from 8 patients, and ranged from 6 to 50 months (mean, 36 mo); 2 patients were lost to follow-up. Detailed clinical, follow-up, and histologic findings in 10 patients with ETV6-RET translocated SC are summarized in Table 5 .
All tumors were treated by surgical excision; in 1 patient the excision was radical with clear surgical margins, in 4 cases the surgical margins were positive, and in 4 additional patients, the tumor infiltration was close (< 0.5 mm) to the surgical margins. Five patients underwent subtotal conservative parotidectomy, in 3 of them in combination with radiotherapy (cases 2, 4, and 7). Residual tumors were treated by radical reexcision with clear surgical margins in 2 patients. Concomitant chemotherapy and radiotherapy was used in 1 patient with high-grade transformed SC complicated by metastatic (Table 6) . †Stevens et al 8 ( Table 2) . Surgical margins: free-0; close (means distance from the tumor <0.5 mm ) -1; positive-2. F indicates female; LVI, lymphovascular invasion; M, male; NA, not available; PN, perineural invasion.
disease at 15 months after surgery (case 7). Clinical and follow-up findings are summarized in Table 5 .
Macroscopic Features
Detailed clinical and morphologic findings in 10 patients with ETV6-RET translocated SC are summarized in Table 6 . The median tumor size was 3.6 cm, with a range of 1.0 to 7.0 cm. Grossly, most tumors were variably invasive: 2 were entirely circumscribed and encapsulated, 1 had focally infiltrative edges, and 7 were predominantly infiltrative.
Microscopic and Immunohistochemical Features
On low power magnification, 3 major growth patterns of SC were identified in our material. First, 3 tumors were well circumscribed and surrounded by a thick, focally uninterrupted, fibrous capsule enclosing a predominantly multicystic growth pattern with multiple mural nodules (Fig. 3A) . The cysts were lined mostly by a single or focally by a double layer of cells with prominent apocrine differentiation including hobnail and vacuolated foamy cells (Figs. 3B, C) , and contained abundant proteinaceous eosinophilic material. The fibrous capsule and septa comprised psammomatoid calcifications in some places (Fig. 3D) . The second pattern was characterized by solid and microcystic growth with a multilobular structure divided by thin fibrous septa (Fig. 4A) . The tumors either lacked a capsule or were only partially encapsulated with prominent infiltrative borders (Fig. 4B) . These cases were predominantly composed of microcystic and slightly dilated glandular spaces filled with a variable amount of eosinophilic homogenous secretory material (Fig. 4C) . The third pattern, prevailing in 3 cases, comprised a prominent fibrosclerotic stroma with isolated tumor cells in small islands or trabeculae, which were seen in the central part of the tumor (Fig. 5A) . In case 7, 2 different growth patterns were seen, in particular low-grade components arranged in multiple macrocystic and microcystic lobules with comedo-like necroses, and highgrade components with limited secretory material and high proliferative activity (Fig. 5B) .
However, most tumors demonstrated 2 or more architectural patterns, with microcystic, tubular, solid, and papillary patterns often occurring together. Regardless of the growth pattern of SC, the tumor cells were often bland looking, with abundant pale pink vacuolated and foamy cytoplasm and with vesicular oval nuclei with a single small but prominent nucleolus. The cytologic features were similar from case to case. The range of nuclear atypia was assessed as grades 1 to 3. Mitotic figures were rare and necrosis was absent. Prominent perineural and intraneural invasion was seen in case 7 (Fig. 5C ). Only 1 patient (case 2) presented with a single periparotideal lymph node metastasis at the time of diagnosis.
Immunohistochemical Findings
By immunohistochemistry, all examined SC cases were positive for S100 protein (Fig. 6A) , mammaglobin (Fig. 6B) , typically in strong and diffuse fashion (secretory material was also positive), and cytokeratin CK7 (Fig. 6C) . GATA-3, SOX-10 ( Fig. 6D) , and STAT5a expression was detected in 3/6, 5/6, and 2/3 cases, respectively. P63 protein was completely negative in most cases, with limited areas of positive peripheral myoepithelial cell staining suggestive of a focal intraductal component in 3 cases. DOG1 was negative in all examined cases.
Proliferative activity was generally low, with a mean MIB1 index of 15% (range, 5% to 40%).
DISCUSSION
Salivary gland tumors are increasingly being found to have characteristic chromosomal rearrangements. SC is a salivary gland tumor that recapitulates the histology and genetics of a rare malignancy of the breast SC. These tumors are defined by the t(12;15)(q13;q15) translocation, a fusion of the ETV6 gene from chromosome 12 and the NTRK3 gene from chromosome 15. The same translocation has been detected in most cases of the infantile fibrosarcomas, congenital mesoblastic nephromas, 13 chronic eosinophilic leukemias, 33 acute myeloid leukemia, 14 and some papillary carcinomas of the thyroid with and without previous irradiation. 18 These groups of tumors are the focus of interest, because tumors with ETV6-NTRK3 fusion translocation respond well to treatment by entrectinib, which is a potent inhibitor of tyrosine kinases TRKA/B/C, ROS1, and ALK. The drug entrectinib is administered orally, is safe and well tolerated, and can cross the blood-brain barrier, so that it can be effective for treatment of brain metastases. 34, 35 Originally it appeared that all cases of SC share the same ETV6-NTRK3 fusion translocation. However, in recent years Ito et al 27 and Skalova et al 26 described altogether 6 cases of SC with the ETV6 gene split detected by FISH, but in which the ETV6 gene appeared to be fused with a gene different to NTRK3. These cases were marked as SCs with ETV6-X fusion.
Herein, we describe a novel ETV6-RET fusion in 10 cases of salivary gland carcinomas with histologic features and IHC profile typical of SC, including the 4 ETV6-X SC cases published previously. 26 The presence of ETV6-RET fusion in SC was proven by at least 3 independent tests (NGS, FISH, RT-PCR), in all but 2 cases (Table 3 , cases 4 and 9). In case 4, NGS and FISH confirmed ETV6-RET fusion but RT-PCR was negative, probably due to low or focal expression of fusion transcript (Table 4 ). Case 9 was the only sample unconfirmed by independent analysis. There was a lack of material for FISH analysis and RT-PCR for ETV6-RET fusion transcript detection was negative. In this case, low quality of RNA rather than low or focal expression is responsible for this result.
The alternative ETV6-RET transcription will be important for treatment of those SCs with uncontrolled regional growth or SCs with metastatic foci, as treatment with entrectinib and similar drugs with the same target specificity will probably be ineffective in these SCs with alternative fusion transcript different from ETV6-NTRK3. The alternative fusion partner different from ETV6-NTRK3 in SC should not be of great surprise, because infantile fibrosarcoma with ETV6-NTRK3 translocation may have alternative EML4-NTRK3 translocation, 36 and there are descriptions of acute myeloid leukemias in which the ETV6 gene fuses with many alternative fusion partners, including ETV6-ABL1, 37 ETV6-LPXN, 38 ETV6-RUNX1, 39 ETV6-NCOA2, 40 and many others.
To our knowledge, ETV6-RET fusions have not been reported in salivary gland tumors so far. Notably, however, recent studies using RNA sequencing have revealed that salivary duct carcinoma (SDC) may also be added to the growing list of gene fusion-positive salivary carcinomas. NCOA4-RET fusions have been found in 2 SDCs. 41 Both NCOA4-RET translocated SDCs were positive for androgen receptors, and the tumors progressed in spite of undergoing concurrent chemoradiation, combination chemotherapy, and dual androgen deprivation therapy. Both patients with NCOA4-RET translocation, however, benefited from RET-targeted therapy. 41 The treatment of SC has varied, ranging from simple excision to radical resection, neck dissection, adjuvant radiotherapy, and/or adjuvant systemic chemotherapy. 1, 42, 43 For patients presenting with a locally advanced, recurrent, or metastatic disease, the treatment options are currently limited and mainly palliative. 42, 43 Therefore, SCs with ETV6-RET fusion translocation must be clearly distinguished from SCs with ETV6-NTRK3 translocation, because the drugs RXDX105 and LOXO 292, effective with various tumors driven with RET gene alterations, are being tested for the treatment. SCs with ETV6-RET translocation might respond much better to these drugs, whereas entrectinib and similar inhibitors of tyrosine kinases TRKA/B/C will probably be ineffective. [44] [45] [46] [47] In summary, a novel finding in our study has been the discovery of a subset of SC patients with ETV6-RET fusions who may benefit from RET-targeted therapy. Many salivary gland malignancies are still included in the group of adenocarcinomas not otherwise specified. We believe that detailed genomic profiling and NGS of a large cohort of these unspecified neoplasms may lead to the identification of novel gene fusions and driver mutations characterizing new clinically relevant subgroups of salivary gland carcinomas. This study highlights that further molecular analyses of salivary gland tumors are warranted and deserve special attention to identify new tumor types with possible therapeutic implications.
